{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:12:47Z","timestamp":1779167567909,"version":"3.51.4"},"reference-count":36,"publisher":"Jaypee Brothers Medical Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.59556\/japi.72.0485","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T06:40:02Z","timestamp":1752216002000},"page":"40-46","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Efficacy of Golimumab in Indian Patients with Active Spondyloarthritis of Ankylosing Spondylitis or Psoriatic Arthritis: A Multicenter, Noncomparative, Open-Label, Real-World Study"],"prefix":"10.59556","volume":"72","author":[{"given":"Sundeep","family":"Upadhyaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikantiah","family":"Chandrashekara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkataraman","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syamasis","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit","family":"Surin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"Rajasekhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit","family":"Nalawade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishita","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanuja","family":"Korde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitendra","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"issue":"(6):","key":"key20250711063957_B1","doi-asserted-by":"crossref","first-page":"747\u2013","DOI":"10.1016\/j.berh.2011.02.002","article-title":"Seronegative spondyloarthritis.","volume":"24","author":"Zochling","year":"2010;","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"(1):","key":"key20250711063957_B2","first-page":"e12629.","article-title":"The delay of diagnosis in spondyloarthropathy patients in a tertiary hospital in Saudi Arabia.","volume":"13","author":"Bedaiwi","year":"2021;","journal-title":"Cureus"},{"issue":"(1):","key":"key20250711063957_B3","doi-asserted-by":"crossref","first-page":"115.","DOI":"10.1186\/s13075-015-0640-3","article-title":"Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype.","volume":"17","author":"FitzGerald","year":"2015;","journal-title":"Arthritis Res Ther"},{"issue":"(7):","key":"key20250711063957_B4","doi-asserted-by":"crossref","first-page":"662\u2013","DOI":"10.1080\/09546634.2019.1605142","article-title":"Psoriatic arthritis for dermatologists.","volume":"31","author":"Gottlieb","year":"2020;","journal-title":"J Dermatolog Treat"},{"issue":"(5):","key":"key20250711063957_B5","first-page":"45\u2013","article-title":"Psoriatic arthritis: an up to date overview.","volume":"15","author":"Hackett","year":"2020;","journal-title":"Indian J Rheumatol"},{"issue":"(1):","key":"key20250711063957_B6","doi-asserted-by":"crossref","first-page":"42\u2013","DOI":"10.1080\/03009742.2021.1997436","article-title":"Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents.","volume":"52","author":"Kerola","year":"2023;","journal-title":"Scand J Rheumatol"},{"issue":"(5):","key":"key20250711063957_B7","doi-asserted-by":"crossref","first-page":"697\u2013","DOI":"10.3899\/jrheum.170150","article-title":"Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT working group.","volume":"44","author":"Ogdie","year":"2017;","journal-title":"J Rheumatol"},{"issue":"(9):","key":"key20250711063957_B8","doi-asserted-by":"crossref","first-page":"1320\u2013","DOI":"10.1002\/acr.22831","article-title":"Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis.","volume":"68","author":"Stolwijk","year":"2016;","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"(1):","key":"key20250711063957_B9","doi-asserted-by":"crossref","first-page":"173.","DOI":"10.1186\/s12955-020-01422-z","article-title":"Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the psoriatic arthritis impact of disease (PsAID) questionnaire.","volume":"18","author":"Coates","year":"2020;","journal-title":"Health Qual Life Outcomes"},{"issue":"(Suppl 1):","key":"key20250711063957_B10","first-page":"S2\u2013","article-title":"Spondyloarthritis in India.","volume":"15","author":"Malaviya","year":"2020;","journal-title":"Indian J Rheumatol"},{"issue":"(1):","key":"key20250711063957_B11","doi-asserted-by":"crossref","first-page":"19\u2013","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.","volume":"82","author":"Ramiro","year":"2023;","journal-title":"Ann Rheum Dis"},{"issue":"(8):","key":"key20250711063957_B12","doi-asserted-by":"crossref","first-page":"465\u2013","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021.","volume":"18","author":"Coates","year":"2022;","journal-title":"Nat Rev Rheumatol"},{"issue":"(10):","key":"key20250711063957_B13","doi-asserted-by":"crossref","first-page":"1285\u2013","DOI":"10.1002\/acr.24025","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloearch and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis.","volume":"71","author":"Ward","year":"2019;","journal-title":"arthritis ResArthritis Care Res (Hoboken)"},{"issue":"(10):","key":"key20250711063957_B14","doi-asserted-by":"crossref","first-page":"767\u2013","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics.","volume":"9","author":"Nelson","year":"2010;","journal-title":"Nat Rev Drug Discov"},{"issue":"(11):","key":"key20250711063957_B15","doi-asserted-by":"crossref","first-page":"1021\u2013","DOI":"10.1007\/s40261-020-00959-7","article-title":"Post-approval safety surveillance study of golimumab in the treatment of rheumatic disease using a United States healthcare claims database.","volume":"40","author":"Ziyadeh","year":"2020;","journal-title":"Clin Drug Investig"},{"issue":"(4):","key":"key20250711063957_B16","doi-asserted-by":"crossref","first-page":"757\u2013","DOI":"10.1136\/annrheumdis-2014-205862","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.","volume":"74","author":"Deodhar","year":"2015;","journal-title":"Ann Rheum Dis"},{"issue":"(9):","key":"key20250711063957_B17","doi-asserted-by":"crossref","first-page":"1689\u2013","DOI":"10.1136\/annrheumdis-2013-204902","article-title":"Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).","volume":"73","author":"Kavanaugh","year":"2014;","journal-title":"Ann Rheum Dis"},{"issue":"(11):","key":"key20250711063957_B18","doi-asserted-by":"crossref","first-page":"3402\u2013","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.","volume":"58","author":"Inman","year":"2008;","journal-title":"Arthritis Rheum"},{"issue":"(4):","key":"key20250711063957_B19","doi-asserted-by":"crossref","first-page":"976\u2013","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.","volume":"60","author":"Kavanaugh","year":"2009;","journal-title":"Arthritis Rheum"},{"issue":"(14):","key":"key20250711063957_B20","doi-asserted-by":"crossref","first-page":"4178.","DOI":"10.3390\/jcm11144178","article-title":"Effectiveness of golimumab as second anti-TNF\u03b1 drug in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis in Italy: GO-BEYOND, a prospective real-world observational study.","volume":"11","author":"D\u2019Angelo","year":"2022;","journal-title":"J Clin Med"},{"issue":"(3):","key":"key20250711063957_B21","doi-asserted-by":"crossref","first-page":"537\u2013","DOI":"10.55563\/clinexprheumatol\/zizo0l","article-title":"Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study.","volume":"39","author":"Flipo","year":"2021;","journal-title":"Clin Exp Rheumatol"},{"issue":"(6):","key":"key20250711063957_B22","doi-asserted-by":"crossref","first-page":"e021082.","DOI":"10.1136\/bmjopen-2017-021082","article-title":"Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.","volume":"8","author":"Kr\u00fcger","year":"2018;","journal-title":"BMJ Open"},{"issue":"(2):","key":"key20250711063957_B23","first-page":"254\u2013","article-title":"High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.","volume":"36","author":"Thomas","year":"2018;","journal-title":"Clin Exp Rheumatol"},{"issue":"(8):","key":"key20250711063957_B24","doi-asserted-by":"crossref","first-page":"2504\u2013","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.","volume":"64","author":"Kavanaugh","year":"2012;","journal-title":"Arthritis Rheum"},{"issue":"(9):","key":"key20250711063957_B25","doi-asserted-by":"crossref","first-page":"1654\u2013","DOI":"10.1093\/rheumatology\/keu132","article-title":"Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.","volume":"53","author":"Bao","year":"2014;","journal-title":"Rheumatology (Oxford)"},{"issue":"(11):","key":"key20250711063957_B26","doi-asserted-by":"crossref","first-page":"3230\u2013","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.","volume":"48","author":"Davis JC","year":"2003;","journal-title":"Arthritis Rheum"},{"issue":"(4):","key":"key20250711063957_B27","doi-asserted-by":"crossref","first-page":"498\u2013","DOI":"10.1136\/ard.2006.058339","article-title":"Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.","volume":"66","author":"Kavanaugh","year":"2007;","journal-title":"Ann Rheum Dis"},{"issue":"(7):","key":"key20250711063957_B28","doi-asserted-by":"crossref","first-page":"1112\u2013","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial.","volume":"71","author":"Mease","year":"2019;","journal-title":"Arthritis Rheumatol"},{"issue":"(5):","key":"key20250711063957_B29","doi-asserted-by":"crossref","first-page":"702\u2013","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT).","volume":"68","author":"Mease","year":"2009;","journal-title":"Ann Rheum Dis"},{"issue":"(9):","key":"key20250711063957_B30","doi-asserted-by":"crossref","first-page":"1276\u2013","DOI":"10.1136\/ard.2007.073098","article-title":"MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.","volume":"67","author":"Rudwaleit","year":"2008;","journal-title":"Ann Rheum Dis"},{"issue":"(2):","key":"key20250711063957_B31","doi-asserted-by":"crossref","first-page":"582\u2013","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).","volume":"52","author":"van der Heijde","year":"2005;","journal-title":"Arthritis Rheum"},{"issue":"(7):","key":"key20250711063957_B32","doi-asserted-by":"crossref","first-page":"2136\u2013","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"54","author":"van der Heijde","year":"2006;","journal-title":"Arthritis Rheum"},{"issue":"(3):","key":"key20250711063957_B33","doi-asserted-by":"crossref","first-page":"587\u2013","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.","volume":"73","author":"Huang","year":"2014;","journal-title":"Ann Rheum Dis"},{"issue":"(4):","key":"key20250711063957_B34","doi-asserted-by":"crossref","first-page":"589\u2013","DOI":"10.3109\/s10165-011-0557-x","article-title":"A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis.","volume":"22","author":"Kobayashi","year":"2012;","journal-title":"Mod Rheumatol"},{"issue":"(1):","key":"key20250711063957_B35","doi-asserted-by":"crossref","first-page":"56.","DOI":"10.1186\/s41927-020-00158-z","article-title":"Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry.","volume":"4","author":"Rahman","year":"2020;","journal-title":"BMC Rheumatol"},{"issue":"(6):","key":"key20250711063957_B36","doi-asserted-by":"crossref","first-page":"343\u2013","DOI":"10.1080\/09546630600967166","article-title":"Use of etanercept for psoriatic arthritis in the dermatology clinic: the experience diagnosing, understanding care, and treatment with etanercept (EDUCATE) study.","volume":"17","author":"Gottlieb","year":"2006;","journal-title":"J Dermatolog Treat"}],"container-title":["Journal of the Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T06:40:07Z","timestamp":1752216007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-72-3-40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.59556\/japi.72.0485"],"URL":"https:\/\/doi.org\/10.59556\/japi.72.0485","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}